Eli Lilly Reports post-marketing Data for Epcoritamab in Ulcerative colitis

Eli Lilly today announced post-marketing results for epcoritamab in patients with ulcerative colitis. The study demonstrated that epcoritamab achieves clinical remission compared to standard of care or placebo. These results provide important insights into the treatment of ulcerative colitis and support the continued development of epcoritamab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.